Keebeck Wealth Management Acquires New Position in TransMedics Group, Inc. $TMDX

Keebeck Wealth Management acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,820 shares of the company’s stock, valued at approximately $387,000.

A number of other hedge funds have also added to or reduced their stakes in TMDX. Silvant Capital Management LLC purchased a new position in shares of TransMedics Group during the second quarter worth approximately $26,000. Harvest Fund Management Co. Ltd bought a new stake in shares of TransMedics Group during the third quarter valued at approximately $29,000. North Star Investment Management Corp. purchased a new stake in shares of TransMedics Group in the first quarter valued at approximately $30,000. Ascentis Independent Advisors purchased a new stake in shares of TransMedics Group in the first quarter valued at approximately $30,000. Finally, Allworth Financial LP grew its stake in TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director directly owned 16,642 shares of the company’s stock, valued at $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

TransMedics Group Trading Up 4.3%

TransMedics Group stock opened at $94.77 on Friday. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. The stock has a market cap of $3.28 billion, a PE ratio of 24.36 and a beta of 1.90. The stock has a 50-day moving average of $77.49 and a two-hundred day moving average of $95.32. TransMedics Group, Inc. has a one year low of $60.10 and a one year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). The company had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business’s revenue was up 20.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.92 EPS. On average, research analysts anticipate that TransMedics Group, Inc. will post 1.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Stifel Nicolaus raised their price objective on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. Piper Sandler reiterated an “overweight” rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Canaccord Genuity Group reissued a “buy” rating and set a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th. Finally, TD Cowen restated a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a research note on Wednesday, July 1st. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $124.18.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.